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Summary The concentration ofcarcinoembryonic antigen (CEA), CA130, CA125, SLX, CA19-9, SPan1, and
tumour-associated glycoprotein 72 (TAG-72) in the culture supernatant of 15 cancer cell lines and in the sera
of 58 cancer patients was measured, and the co-expression of these antigens was examined by double determinant immunoradiometric assays. The high correlation coefficient of the concentrations and significant binding in the double determinant assays indicated a close relationship between CA125 and CA130 and
between CA19-9 and SPanl. There was variable binding of the '25I-labelled anti-SLX, anti-CA19-9, and
anti-SPanl antibodies to anti-CA130 beads that had been pre-incubated with the culture supernatants, suggesting the presence of the epitopes of SLX, CA19-9, and SPanl on the molecule expressing CA130.
Similarly, the epitopes of SLX, CA19-9, and SPanl could be present on the molecule expressing CEA.
'25I-labelled anti-CA19-9, anti-SLX, and anti-TAG-72 antibodies were bound in variable proportions to
anti-CA130 beads or to anti-CEA beads that had been pre-incubated with patients' sera. However, CEA and CA130 were not expressed on the same molecule, either in the culture supernatant, or in patients' sera. In
conclusion, the carbohydrate epitopes of CAI9-9, SPan 1, SLX, and TAG-72 could be present on the molecule
recognised by the anti-CA130 or anti-CEA antibody; however, the epitopes of CA130 and CEA did not
co-exist on the same molecule.
The measurement of tumour-associated antigens in body
fluids is useful for the diagnosis and monitoring of cancer
patients (Sears et al., 1982; Bast et al., 1983; Sakahara et al.,
1986). Tumour-associated antigens recognised by different
monoclonal antibodies are sometimes similar to each other
and can be co-expressed on the same molecule (Hanisch et
al., 1985; Lan et al., 1987; Yu et al., 1991). We examined the
similarity and co-expression of seven tumour markers, car-
cinoembryonic antigen (CEA), CA130, CA125, SLX, CAl9-
9, SPanl, and tumour-associated glycoprotein 72 (TAG-72),
in the culture supernatant of 15 cancer cell lines and in the
sera of 58 cancer patients. Co-expression of the antigenic
determinants, detected by commercially available monoclonal
antibodies, was tested by double determinant immunoradio-
metric assay.
Materials and methods
Immunoradiometric assay
Tumour markers were measured with commercially available
kits, all of which are based on immunoradiometric assay
using monoclonal antibodies. The kits contain an '251-labelled
antibody and polystyrene beads that are coated with the
same or another antibody.
The CEA and SPanl immunoradiometric assay kits were
obtained from Dainabot (Tokyo, Japan). The immobilised
anti-CEA antibody is a murine monoclonal antibody that
recognises a peptide epitope common to CEA, nonspecific
cross-reacting antigen (NCA), and NCA-2. The tracer anti-
CEA antibody is a monoclonal antibody that recognises a
peptide epitope present on both CEA and NCA-2, but not
on NCA. The monoclonal antibody, SPanl, is coated on the
beads and labelled with 1251 (Chung et al., 1987; Ho et al.,
1988). The antigen recognised by SPanl is also designated as
SPanl. The CA125, CA19-9 and TAG-72 assay kits were
obtained from Centocor (Malvern, PA, USA). In the CA125
assay, the monoclonal antibody, OC125, is used for both
catcher and tracer (Bast et al., 1983; Klug et al., 1984). The
CA19-9 assay kit employs the monoclonal antibody 19-9,
both as a catcher and as a tracer antibody (Sears et al., 1982;
Del Villano et al., 1983). The monoclonal antibody, CC49, is
immobilised to beads and the monoclonal antibody, B72.3, is
labelled with 1251I in the TAG-72 assay (Johnson et al., 1986;
Muraro et al., 1988). CA130 was measured with a kit that
consisted of solid-phase 145-9 monoclonal antibody and 1251_
labelled 130-22 monoclonal antibody (Matsuoka et al., 1987;
Kunimatsu et al., 1988; Saga et al., 1990). The CA130 kit
was supplied by Daiichi Radioisotope Laboratory (Tokyo,
Japan). SLX, known as sialyl stage-specific embryonic
antigen 1 (sialyl-SSEA-1), was measured using a kit provided by Otsuka Assay (Tokushima, Japan). The monoclonal
antibody, FH-6, which recognises 2-3 sialyl Lex-i, was used
for both catcher and tracer (Fukushi et al., 1984; Kannagi et
al., 1986). All assays were performed following the manufac-
turers' instructions.
New double determinant immunoradiometric assays were
constructed by combining the antibody-coated beads from
one kit and the tracer antibody from another kit. Fifty microliters of sample and 150Itl of phosphate buffered saline
(0.05 M, pH 7.5), containing 0.25% bovine serum albumin,
were incubated with one antibody-coated bead. After incuba-
tion at room temperature with gentle shaking for 4 h, the
bead was washed three times with 1 ml of physiological
saline. One hundred microliters of '251-labelled antibody was
then added to the bead, which was then incubated for
another 20 h at room temperature with gentle shaking. After
three washes, the radioactivity bound to the bead was mea-
sured; it was shown as the percentage of the total added
radioactivity.
Conventional and heterologous immunoradiometric assays
were carried out in duplicate for each sample.
Cell lines
Culture supernatants were obtained from five lung adenocar-
cinoma cell lines, VMRC-LCD, RERF-LC-OK, ABC-1, A549 and PC-9, three gastric cancer cell lines, NUGC-2,
NUGC-3 and KATOIII; four colon cancer cell lines, LoVo,
SWl 116, LS180, and LSl 74T; two ovarian cancer cell lines,
SHIN3 and HTOA; and the uterine cervical adenocarcinoma
cell line, TMCC-1. VMRC-LCD, RERF-LC-OK, ABC-1,
A549, NUGC-2, NUGC-3, KATOIII, and LoVo were
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Table I Concentrations of tumour markers in culture supernatant
CEA CA130 CA.125 SLX CA.19-9 SPani TAG-72
Cell line (ng ml') (Uml-') (Umi-') (Uml-') (Uml-') (Uml-') (Umi-')
Lung cancer
VMRC-LCD 6.3 10.5 5.1 5.2 4.0 0 2.3
RERF-LC-OK 0.0 11.8 4.1 7.9 4.0 1 2.3
ABC-1 0.0 672.9 708.0 17.4 4.0 0 4.8
A549 2.3 173.6 186.0 11.5 4.0 0 3.6
PC-9 2.6 3875.0 4220.0 4716.0 1.8 0 2.2
Gastric cancer
NUGC-2 0.6 24.9 15.2 9.0 38.0 6 2.3
NUGC-3 0.3 63.7 59.7 7.5 6.0 1 2.4
KATOIII 123.4 9.9 4.7 88.4 1270.0 160 2.9
Colon cancer
LoVo 81.3 32.3 21.0 5.5 91.0 26 2.7
SW1116 60.8 88.3 134.6 109.6 11220.0 >1500 2.7
LS180 14.0 13.2 5.2 41.5 440.0 72 42.0
LS174T 24.4 15.6 4.8 48.2 770.0 185 36.9
Ovarian cancer
SHIN3 5.0 354.0 499.0 23.6 5.0 0 3.2
HTOA 0.0 768.0 1130.0 433.0 47.6 18 3.0
Uterine cancer
TMCC-1 0.5 987.8 1050.0 8.4 4.0 1 11.5
Table II Two double determinant assays, using anti-CA130 and
anti-CA19-9 as a catcher (bound%)
Catcher: 145-9 Catcher: 19-9
Cell line Tracer: OC125 Tracer: SPanI
VMRC-LCD 0.7 0.2
RERF-LC-OK 0.8 0.1
ABC-1 31.4 0.1
A549 10.6 0.3
PC-9 56.3 0.2
NUGC-2 1.4 2.6
NUGC-3 3.5 0.7
KATOIII 0.7 58.0
LoVo 1.6 9.0
SW1116 6.1 78.8
LS180 0.7 27.2
LS174T 0.8 57.4
TMCC-1 38.1 0.1
SHIN3 22.1 0.2
HTOA 40.6 3.6
These high correlations mean parallelism of the concentra-
tions between CA125 and CA130 and between CA19-9 and
SPanl. The binding of '25I-labelled anti-CA125 to anti-
CA130 coated beads and 125I-labelled anti-SPanl to anti-
CA19-9 coated beads that had been pre-incubated with
supernatants is shown in Table II. '251-labelled anti-CA125
bound to anti-CA130 coated beads in accordance with the
concentrations of both CA130 and CA125. These results
suggest that anti-CA125 and anti-CA130 antibodies recognise
the same molecule. Similarly, the binding of 251I-labelled
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supplied by the Japanese Cancer Research Resources Bank
(Tokyo, Japan). SWI 116, LS180, and LS174T were supplied
by the American Type Culture Collection (Rockville, MD,
USA). SHIN3, HTOA, and TMCC-1 were generously pro-
vided by Dr Y. Kiyozuka (Nara Medical College, Nara,
Japan), Dr I Ishiwata (Ishiwata Hospital, Ibaragi, Japan),
and Dr Sakamoto (Tokyo Medical College, Tokyo, Japan),
respectively (Kiyozuka, 1987; Ishiwata et al., 1987;
Sakamoto, 1988). Cells were cultured in RPMI-1640 medium
(Nissui, Tokyo, Japan) supplemented with 10% of foetal
bovine serum (Gibco, Grand Island, NY, USA). The
SWI116 culture supernatant was fractionated by Sephacryl
S-300 column chromatography.
Patients' sera
Sera were obtained from 19 patients with colon cancer, 16
patients with pancreatic cancer, and 23 patients with ovarian
cancer. The diagnoses were based on histological examina-
tions of biopsied or surgically removed specimens. Sera were
stored at -40°C until use.
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Results
The concentrations of tumour markers in the culture super-
natant of cell lines are shown in Table I. The correlation
coefficients for CA125 and CA130 levels and for CA19-9 and
SPanl antigen levels were 0.981 and 0.940, respectively.
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Figure 1 Double determinant immunoradiometric assay for cul-
ture supernatant, using anti-CA130 antibody as a catcher. The
percentage of added radioactivity of tracers bound to the bead
was plotted. The antigen recognised by the tracer antibody is
shown under each column.
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anti-SPanl to anti-CA19-9 coated beads was also correlated
with both CA19-9 and SPanl antigen values, suggesting co-
expression of 19-9 and SPanl epitopes on the same molecule.
Figure 1 shows the results of double determinant assays of
the culture supernatants using anti-CA130 antibody as a
catcher. Anti-SLX, anti-CA19-9, and anti-SPanl antibodies
bound anti-CA130 beads variably. This suggests that the
antigenic determinants of SLX, CA19-9, and SPanl were
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Figure 2 Double determinant immunoradiometric assay for cul-
ture supernatant, using anti-CEA antibody as a catcher. The
percentage of added radioactivity of tracers bound to the bead
was plotted. The antigen recognised by the tracer antibody is
shown under each column.
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present on the molecule expressing CAl30. Similarly, it is
possible that the epitopes of SLX, CA19-9, and SPan1 could
be present on the molecule expressing CEA (Figure 2). There
was no binding of anti-CEA tracer to the anti-CA130 beads
or of anti-CA130 tracer to the anti-CEA beads.
The culture supernatant of the SW 1116 cell line was sub-
jected to Sephacryl S300 gel chromatography and each frac-
tion was assayed (Figure 3). CEA was detected at fraction
number 50, corresponding to a molecular weight of 180-
200kD. CA19-9, SPanl, SLX, and CA130 were detected at
the void volume of fraction number 40, corresponding to a
molecular weight of more than 1OOOkD. The binding of
anti-CEA, anti-CA19-9, anti-SPanl, anti-SLX, and anti-
CA130 tracers to anti-CA130 beads and anti-CEA beads in
fractions 40 and 50 is shown in Figures 4 and 5. The
antigenic determinants of CA19-9, SPanl, and SLX were
present in the same fraction (more than 1000 kD) recognised
by the anti-CA130 antibody (Figure 4). The anti-CA19-9,
anti-SPanl, and anti-SLX antibodies bound anti-CEA beads
in fraction 40, suggesting that large molecules of more than
1OOOkD express both CEA and the epitopes of CA19-9,
SPanl, and SLX (Figure 5). Epitopes of CA19-9 and SPanl
were also present on the 180kD CEA molecule in fraction
50. There was no binding of the anti-CA130 tracer to the
anti-CEA beads or of the anti-CEA tracer to the anti-CA130
beads in either fraction 40 or fraction 50.
The concentration of tumour markers in patients' sera is
shown in Table III. The correlation coefficient for CA19-9
and SPan1 antigen was very high (r = 0.942), as it was in the
culture supernatant. The correlation coefficient for CA130
and CA125 was also high (r = 0.973). The anti-CA19-9, anti-
SLX, and anti-TAG-72 bound variably to both anti-CA130
and anti-CEA beads that had been pre-incubated with
patients' sera (Figures 6 and 7, Table IV).
Discussion
The good correlation of CA130 and CA125 concentrations,
together with the finding that '251-labelled anti-CA125 bound
to anti-CA130 coated beads that had been pre-incubated
with culture supernatant, suggests that anti-CA125 and anti-
CA130 recognise the same molecule. However, because anti-
CA130 antibodies do not compete with anti-CA125 antibody
for the CA125 epitope in the immunoradiometric assay, the
epitope of CA130 is different from that of CA125 (Matsuoka
et al., 1987; Kunimatsu et al., 1988; Saga et al., 1990).
Although serum concentrations of CA130 and CA125 show
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Figure 3 Concentrations of tumour-associated antigens in the SW1116 culture supernatant fraction after fractionation by
Sephacryl S300 column chromatography. Vo indicates void volume position, and human IgG and albumin are eluted at the
positions IgG and Alb, respectively.
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good coincidence in most patients (Saga et al., 1990), we
have found high CA125 and normal CA130 levels in the sera
of five patients in a series of more than 8000 samples
(Hosono et al., 1992). We did not find any malignant diseases
in any of these five patients. Measurement of circulating
CA130 may resolve the problems of CA125 false-positive
cases.
Spanl antigen and CA19-9 were also found to be co-
expressed on the same molecule. While anti-CA19-9 antibody
competes with anti-SPanl antibody for the SPanl epitope
(Ho et al., 1988), anti-CA19-9 does not react with colonic
cancer tissues from patients with Lewisa, Lewisb negative
phenotype, although anti-SPanl does (Chung et al., 1987).
SPanl would be a better tumour marker in patients with
Lewisa'b- phenotype.
The epitopes of CA19-9, SPanl, SLX, and TAG-72 are
carbohydrates with sialic acid (Ho et al., 1988; Fukushi et al.,
1984; Magnani et al., 1982; 1983; Kjeldsen et al., 1988).
Although the epitopes of CA125 and CA130 have not yet
been fully determined, the antigen defined by anti-CA125 and
anti-CA130 antibodies has been shown to be a heat-labile
large molecular weight glycoprotein (Matsuoka et al., 1987;
Masuho et al., 1984; Davis et al., 1986). The co-expression of
tumour-associated carbohydrate epitopes has been suggested
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on large molecular weight mucin; CA125 and CAl9-9 have
been found to be present on a mucin glycoprotein from
human milk (Hanisch et al., 1985). Epitopes of CA19-9 and
DU-PAN-2 may be co-expressed on the same mucin mole-
cule in varying proportions (Lan et al., 1987). A fraction of
ascites fluids from different ovarian cancer patients was
Table III Concentrations of tumour markers in sera of 58 cancer
patients
Unit Mean Range Cut-off Positivea
CEA ngml-' 184 1-4740 2.5 42 (72%)
CA19-9 U ml-' 23100 4-940000 37 40 (69%)
SPanI Uml-' 1108 2-21100 30 44 (76%)
SLX Uml-' 94 27-857 38 40 (69%)
CA130 U ml- 512 5-6291 35 42 (72%)
CA130b U ml- 1079 12-6291 35 20 (87%)
CA125b U ml' 1092 18-6485 35 21 (91%)
TAG-72 U ml-' 178 2-2970 4 32 (55%)
aNumber ofpositivecases and positive rate based on the cut-offvalue
shown in the 5th column. bCA125 and CA130 concentrations in 23
patients with ovarian cancer.
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Figure 4 Double determinant immunoradiometric assay for frac-
tions 40 and 50 of the SW1116 culture supernatant, using
immobilised anti-CA130 antibody. Monoclonal antibodies
against CEA, CA19-9, SPanl, SLX and CA130 were used as a
tracer. The vertical axis shows the percentage of added radioac-
tivity bound to the bead.
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Figure 6 Double determinant immunoradiometric assay for
patients' sera, using anti-CA130 antibody as a catcher. The
percentage of added radioactivity of tracers bound to the bead
was plotted. The antigen recognised by the tracer antibody is
shown under each column.
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Figure 5 Double determinant immunoradiometric assay for frac-
tions 40 and 50 of the SWI 116 culture supernatant, using
immobilised anti-CEA antibody. Monoclonal antibodies against
CEA, CA19-9, SPanl, SLX and CA130 were used as a tracer.
The vertical axis shows the percentage of added radioactivity
bound to the bead.
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Figure 7 Double determinant immunoradiometric assay for
patients' sera, using anti-CEA antibody as a catcher. The percen-
tage of added radioactivity of tracers bound to the bead was
plotted. The antigen recognised by the tracer antibody is shown
under each column.
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Table IV Positive case in double determinant assays in patients'
sera
Immunoadsorbent
CA-130 CEA
Cut-off Positive Cut-off Positive
Indicator
CA19-9 2.3 11/58 3.6 6/58
SLX 4.2 24/58 1.8 6/58
TAG-72 2.1 2/58 1.2 7/58
aIn each double determinant assay the mean plus two standard
deviations of the bound % in the group of patients whose serum
concentrations ofone or both ofthe corresponding determinants were
negativewassetasacut-offvalue. Thecut-offvalue ofeachdeterminant
was shown in Table III.
shown to contain moieties which bound to anti-CA125 anti-
body on a solid phase immunoadsorbent and which also
bound the '25I-labelled anti-CA19-9, anti-TAG-72, anti-DF3,
or anti-CA3632 monoclonal antibodies in a double deter-
minant immunoradiometric assay (Yu et al., 1991). The pre-
sent study demonstrated that epitopes of CA19-9, SPanl,
SLX and TAG-72 could be present on the molecule express-
ing the epitope of CA130.
An interesting finding was the presence of the epitopes of
CA19-9, SPanl, SLX and TAG-72 on the molecule express-
ing CEA. Since the solid-phase monoclonal antibody in the
CEA kit recognises a peptide epitope common to CEA,
NCA, and NCA-2, the molecules caught by the anti-CEA
beads may thus be not only CEA, but also NCA or NCA-2.
The molecular weight of CEA or CEA-associated antigens is
less than 180 kD. The molecules recognised by anti-CA19-9,
anti-SPanl, anti-SLX, and anti-TAG-72 antibodies have been
reported to be large molecular weight glycoproteins ranging
from 200 kD to over 5000 kD (Lan et al., 1987; Johnson et
al., 1986; Kannagi et al., 1986; Magnani et al., 1983). In this
study, we found molecules expressing both CEA and sialylat-
ed carbohydrate epitopes to be distributed both in void
volume fraction and in the fraction corresponding to a mole-
cular weight of 180 kD after fractionation of the SWI 116
culture supernatant on Sephacryl S300. It is possible that the
large molecular weight species may be a glycoprotein com-
plex containing both CEA and the carbohydrate epitopes;
further characterisation is thus required. In any case, the
molecule recognised by the anti-CEA antibody could have
CA19-9, SPanl, SLX, or TAG-72 epitopes.
The epitope of CA130 has not yet been clearly demon-
strated; however it is considered to be composed of, at least
in part, conformationally dependent peptide (Matsuoka et
al., 1987). The peptide epitope of CEA and the peptide-
related epitope of CA130 were not present on the same
molecule.
The present study revealed that some of the tumour-associ-
ated epitopes were co-expressed on the same molecule. This
would be true for other monoclonal antibodies recognising
tumour-associated antigen. There are three cases in the
similarity and co-expression. First, two antibodies recognize
almost the same epitope, such as CA19-9 and SPanl. Secon-
dary, two different epitopes are consistently co-expressed on
the same molecule, such as CA125 and CA130. Finally, an
epitope is expressed in varying proportions on the molecule
bearing another epitope, such as several carbohydrate
epitopes on CEA or CA130 molecule.
Although we did not examine the sensitivity or specificity
of the newly developed double determinant assay extensively,
it may be possible to obtain better assay systems with greater
sensitivity and specificity by using new combinations of
monoclonal antibodies. Indeed, improvement of assay sen-
sitivity has already been shown in a heterologous assay using
anti-CA125 and anti-CA130 antibodies (Kunimatsu et al.,
1988).
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